MiMedx Group, Inc. (NASDAQ:MDXG) CAO Sells $635,278.80 in Stock

MiMedx Group, Inc. (NASDAQ:MDXG) CAO William Frank Iv Hulse sold 81,446 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the sale, the chief accounting officer now owns 494,774 shares in the company, valued at approximately $3,859,237.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

MiMedx Group Stock Down 0.2 %

Shares of NASDAQ MDXG traded down $0.02 during trading on Wednesday, hitting $8.10. 670,387 shares of the company traded hands, compared to its average volume of 709,348. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The business’s fifty day moving average is $8.51 and its 200 day moving average is $7.80. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of 14.73 and a beta of 1.97. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.07. The business had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Equities research analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Phocas Financial Corp. acquired a new stake in shares of MiMedx Group in the 4th quarter worth about $2,016,000. Paradigm Capital Management Inc. NY raised its stake in shares of MiMedx Group by 0.5% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company’s stock worth $45,082,000 after purchasing an additional 22,131 shares during the last quarter. Virtus Fund Advisers LLC bought a new position in shares of MiMedx Group in the fourth quarter valued at approximately $35,000. Virtus Investment Advisers Inc. purchased a new position in shares of MiMedx Group during the fourth quarter valued at approximately $335,000. Finally, State of Wyoming grew its holdings in MiMedx Group by 16.3% during the fourth quarter. State of Wyoming now owns 201,111 shares of the company’s stock worth $1,935,000 after buying an additional 28,230 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.